Mazdutide

Mazdutide

Mazdutide, also known as IBI-362 or LY3305677, is a GLP-1 and glucagon receptor dual agonist developed by Innovent Biologics. Innovent submitted the New Drug Application (NDA) to China’s National Medical Products Administration (NMPA) in early 2024; official approval for chronic weight management was granted on June 27, 2025 [3]. The compound remains investigational outside China as of mid 2026. Phase 3 clinical trials published in the New England Journal of Medicine (2025) [1] and JAMA (2026) [2] have evaluated it for weight reduction, liver fat management, and glycemic control in type 2 diabetes.

GLP-1 receptor agonism (mechanism shared with Semaglutide and Tirzepatide):

• Promotes appetite suppression and reduces caloric intake
• Slows gastric emptying, prolonging satiety after meals
• Stimulates glucose-dependent insulin secretion, supporting glycemic control in type 2 diabetes

Glucagon receptor agonism (Mazdutide’s defining differentiator):

• Increases energy expenditure at the cellular level, adding a caloric utilization pathway absent from pure GLP-1 agents
• Stimulates hepatic lipid metabolism and promotes hepatic fat oxidation, driving the liver fat reduction that distinguishes Mazdutide from GIP-axis agents such as Tirzepatide
• These mechanistic effects were confirmed in Phase 3 GLORY-1 and GLORY-2 trials, demonstrating clinically meaningful liver fat reduction beyond what GLP-1/GIP agents achieve [1], [2]

The combination of GLP-1 and glucagon receptor activity targets two key drivers of obesity simultaneously: reduced food intake and increased energy expenditure. This additive metabolic effect is the mechanistic basis for Mazdutide’s position as a weight loss and metabolic peptide in populations where liver disease is a complicating factor.

Mazdutide Peptide Benefits & Trial Data

Phase 3 clinical development programs have now reported full Mazdutide data across populations with obesity, type 2 diabetes, and metabolic liver disease. All efficacy claims below reference specific published trial data.

Weight Reduction – Phase 3 data

• GLORY-1 (Phase 3, NEJM, May 2025) [1]: In a Phase 3 double-blind, placebo-controlled trial in Chinese adults with obesity or overweight, Mazdutide 6 mg achieved 14.84% mean weight loss at 48 weeks versus -0.47% with placebo; 49.5% of participants in the 6 mg group achieved ≥15% weight reduction
• GLORY-2 (Phase 3, JAMA, June 2026) [2]: A Phase 3 randomized clinical trial evaluating Mazdutide 9 mg in Chinese adults with obesity (BMI ≥30 kg/m²) reported 18.55% mean weight reduction at 60 weeks (ITT population) versus 3.02% with placebo; 44.0% of participants achieved ≥20% weight reduction (versus 2.6% placebo); continuous weight loss was observed through 60 weeks with no plateau
• The dual-agonist design’s complementary effects on appetite regulation and energy expenditure are proposed to underlie the progressive weight reduction observed across both trials

Liver Fat Reduction – Phase 3 Data (strongest clinical differentiator)

• GLORY-1 subgroup (ADA 2024 exploratory analysis) [1]: Among participants with baseline liver fat ≥10%, Mazdutide 6 mg achieved 80.2% reduction in liver fat content
• GLORY-2 subgroup [2]: Among participants without type 2 diabetes with baseline liver fat ≥10%, Mazdutide 9 mg achieved 71.9% mean reduction in liver fat content versus a 5.1% increase in the placebo group
• The glucagon receptor pathway is the proposed driver of hepatic lipid oxidation effects; these outcomes represent a clinically meaningful differentiator from GLP-1 and GIP-axis agents

Glycemic Control in Type 2 Diabetes – Phase 3 data

• Phase 3 studies have reported HbA1c reductions and fasting glucose improvements consistent with GLP-1 receptor activity; GLORY-2 reported 10.71% weight loss in participants with type 2 diabetes alongside reductions in fasting glucose and HbA1c
• Findings support evaluation of Mazdutide as a metabolic therapy beyond weight loss alone

Safety and Tolerability – Phase 3 confirmed

• Phase 3 GLORY-1 and GLORY-2 safety profiles confirmed Phase 2 findings: gastrointestinal adverse events (nausea, vomiting, diarrhea) were most common during dose escalation, and no unexpected safety signals were identified [1], [2]
• GLORY-2 adverse event rates at 9 mg: vomiting 53.1%, nausea 46.9%, diarrhea 39.4%; all were mild to moderate and transient, and most occurred during the titration phase
• Data presented at the American Diabetes Association Scientific Sessions 2024 further characterized the tolerability profile across dosing cohorts

Mazdutide Dosage, Dosing Chart & Storage

Mazdutide dosing information is derived from Phase 3 clinical trials and NMPA regulatory submissions. As of mid 2026, NMPA-approved dosing exists within China; no approved protocol exists outside China.

NMPA-approved Dosing in China

• 4 mg once weekly subcutaneously (approved)
• 6 mg once weekly subcutaneously (approved)
• 9 mg dose: NDA submitted to NMPA for expanded approval following GLORY-2 results; under review as of mid 2026 [3]

GLORY-2 Titration Schedule (trial-derived framework for 9 mg)

• Initiation: 3 mg once weekly
• Escalation: increase by 3 mg every 4 weeks
• Maintenance dose: 9 mg reached at week 8
• Gradual dose escalation is standard to reduce the frequency and severity of gastrointestinal adverse events

Practitioners outside China should note that no universally accepted Mazdutide dosing protocol exists beyond China’s NMPA-approved indication. Any off-trial use requires individualized clinical assessment and consideration of local regulations.

Storage (current as of mid 2026)

• Store at 2–8°C; protect from direct light; do not freeze
• Maintain cold-chain handling during transport
• Verify storage requirements using the most current product documentation available in your jurisdiction

Mazdutide Side Effects, Safety & Legal Status

Phase 3 data from GLORY-1 and GLORY-2 have confirmed and extended the safety profile observed in Phase 2 development.

Reported adverse events include:

Nausea, vomiting, diarrhea — most frequent, occurring predominantly during dose escalation; mild to moderate and transient in both Phase 3 trials [1], [2]

Reduced appetite; abdominal discomfort

Effects generally diminish over time with the gradual titration approach used in Phase 3 protocols

Glucagon Receptor Consideration

Mazdutide may produce modest increases in heart rate due to glucagon receptor activity, consistent with the broader class. Individuals with cardiovascular concerns may warrant additional monitoring.

Long-term Safety

Phase 3 GLORY-1 and GLORY-2 safety data are now available and confirm no unexpected safety signals. Longer-term follow-up beyond 60 weeks and broader population data remain areas for continued study.

Current Regulatory Status

• China: NMPA-approved for chronic weight management (June 27, 2025) [3]; approved doses: 4 mg and 6 mg once weekly; 9 mg dose NDA accepted for review (late 2025)
• United States: Not FDA-approved; investigational only
• European Union: Not EMA-approved
• Australia: Not TGA-approved
• Other jurisdictions: Regulatory status varies and continues to evolve

Clinicians should verify local regulations before considering procurement, research, or prescribing activities.

Mazdutide vs Retatrutide & Mazdutide vs Tirzepatide

As dual- and triple-agonist therapies continue to emerge, clinicians frequently compare Mazdutide with other leading metabolic agents. Understanding mechanistic and regulatory differences helps inform evidence-based evaluations.

Mazdutide vs Retatrutide

Mazdutide and Retatrutide both target glucagon receptors to drive liver fat reduction and cellular energy expenditure. However, Retatrutide incorporates GIP receptor activation for a triple-agonist profile, introducing an adipose tissue metabolic pathway absent in Mazdutide’s dual-agonist design.

Their regulatory status also differs substantially: Mazdutide is NMPA-approved in China (June 2025) with completed Phase 3 data published in NEJM [1] and JAMA [2], whereas Retatrutide remains fully investigational within the ongoing global Phase 3 TRIUMPH program. When multi-pathway adipose metabolism is the core research variable, Retatrutide’s triple-agonist mechanism is highly distinct. Conversely, when established regulatory access or documented clinical liver fat outcomes are paramount, Mazdutide presents a more definitive evidence base. Researchers who choose to buy Retatrutide for comparative triple-agonist protocols will find it provides a sharp mechanistic contrast to Mazdutide’s dual-pathway approach.

Mazdutide vs Tirzepatide

The comparison between Mazdutide and Tirzepatide centers on their differing secondary receptors. While Tirzepatide utilizes GIP co-agonism alongside GLP-1, Mazdutide pairs GLP-1 with glucagon receptor activation. No head-to-head randomized controlled trials are currently available.

Tirzepatide is supported by extensive global approvals and historical SURMOUNT-1 data demonstrating roughly 22% weight reduction. However, Mazdutide now delivers comparable Phase 3 evidence—with GLORY-1 showing a 14.84% weight loss at 6 mg [1] and GLORY-2 demonstrating an 18.55% mean ITT weight reduction at 9 mg [2], approaching the efficacy scale of Tirzepatide. Mazdutide’s clear differentiator is its glucagon component, which actively promotes hepatic fat oxidation. This provides a clear advantage in protocols where metabolic liver fat resolution is prioritized alongside weight loss. Researchers who decide to buy Tirzepatide for comparative tracking can utilize its well-characterized GLP-1/GIP profile as a highly stable reference point against Mazdutide’s glucagon-driven cellular mechanics.

Where Can Practitioners Buy Mazdutide Online?

Mazdutide is an investigational research compound available for purchase by qualified professionals only outside China, and is not intended for personal, therapeutic, or clinical use outside of authorized research settings or NMPA-approved channels. Practitioners looking to order Mazdutide from a verified research-grade supplier should source only from vendors who can provide verifiable purity documentation, LOT number traceability, and a certificate of analysis for each batch. These standards are especially important when buying online, where supplier transparency and product quality vary widely.

Medical Spa Rx’s professional support team offers sourcing guidance and documentation support to help licensed professionals identify qualified suppliers and evaluate wholesale buying options. Practitioners are encouraged to contact Medical Spa Rx’s professional support team directly for guidance and direction on supplier standards, documentation requirements, and research-grade sourcing considerations when looking to buy Mazdutide wholesale. Regulatory access in your jurisdiction should be confirmed before any procurement decision.

FAQs

1. What is Mazdutide?

Mazdutide is a GLP-1 and glucagon receptor dual agonist developed by Innovent Biologics, also known by development codes IBI-362 and LY3305677. It belongs to the weight loss and metabolic peptide category. As of mid 2026, it was approved in China by the NMPA on June 27, 2025 for chronic weight management and remains investigational outside China, with no FDA, EMA, or TGA approval.

2. What does Mazdutide peptide do?

Mazdutide activates both GLP-1 and glucagon receptors. GLP-1 signaling promotes appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion. Glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation, driving liver fat reduction beyond what pure GLP-1 agents achieve. Phase 3 trials confirm these additive metabolic effects in clinical populations.

3. What is Mazdutide used for?

Phase 3 GLORY-1 demonstrated 14.84% mean weight loss at 48 weeks with 6 mg versus placebo, and GLORY-2 demonstrated 18.55% mean weight loss at 60 weeks with 9 mg. Liver fat reductions exceeding 70% were observed in relevant subgroups. Additional applications include glycemic control in type 2 diabetes. The NMPA-approved indication in China (June 2025) is chronic weight management.

4. What is the Mazdutide dosage?

NMPA-approved dosing in China is 4 mg and 6 mg once weekly subcutaneously; the 9 mg dose NDA is under review in China following GLORY-2 results. Outside China, no approved protocol exists; Phase 3 trials used gradual titration starting at 3 mg and escalating by 3 mg every 4 weeks to reach 9 mg at week 8. All dosing outside China is trial-derived and requires individualized assessment.

5. How does Mazdutide compare to Tirzepatide?

Mazdutide combines GLP-1 and glucagon receptor agonism; Tirzepatide combines GLP-1 and GIP receptor agonism. No head-to-head trial exists. Tirzepatide has broader regulatory approval and SURMOUNT-1 data showing approximately 22% weight loss. Mazdutide now has Phase 3 evidence approaching these outcomes (18.55% at 9 mg), with its primary differentiator being glucagon-mediated liver fat reduction.

6. How does Mazdutide compare to Retatrutide?

Retatrutide is a GLP-1/GIP/glucagon triple agonist; Mazdutide is a GLP-1/glucagon dual agonist. Both incorporate glucagon-mediated metabolic effects including liver fat reduction. Retatrutide adds the GIP arm for additional adipose metabolic activity. Mazdutide is NMPA-approved in China (June 2025) with Phase 3 data published; Retatrutide remains investigational in Phase 3 TRIUMPH with no approvals.

7. Where can practitioners buy Mazdutide?

Qualified licensed professionals evaluating research-grade Mazdutide should first verify regulatory requirements and import conditions in their jurisdiction; the compound is NMPA-approved in China and available through authorized pharmaceutical channels there. Medical Spa Rx’s professional support team provides sourcing guidance, documentation support, and direction on verified suppliers offering wholesale pricing. Practitioners should prioritize vendors who provide purity documentation, LOT number traceability, and a certificate of analysis when buying Mazdutide online.

Sources

1. Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. doi:1056/NEJMoa2411528
2. Gao L, Jiang H, Cai H, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. Published online June 7, 2026. doi:10.1001/jama.2026.8142
3. Shanghai Municipal Government. Weight loss medicine Mazdutide approved for chronic weight management in China. Published July 2, 2025. https://english.shanghai.gov.cn/en-Latest-WhatsNew/20250702/110d07c0955546378d8ace318a418e6b.html
4. Ji L, Gao L, Jiang H, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022;54:101691. Published 2022 Oct 7. doi:10.1016/j.eclinm.2022.101691

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.